Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Therapeutic Advances in Neurological Disorders
|
March 18, 2025
Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
Robin L Avila, Nicole S Croteau, Fei Tang, et al.
Cureus
|
December 29, 2021
Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
Doran Ksienski, Pauline T Truong, Nicole S Croteau, et al.
Journal of Geriatric Oncology
|
October 16, 2021
Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab
Doran Ksienski, Pauline T Truong, Nicole S Croteau, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 6, 2021
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort
D Ksienski, P T Truong, E S Wai, et al.
BMC Health Services Research
|
February 28, 2018
Reducing time-to-unit among patients referred to an outpatient stroke assessment unit with a novel triage process: a prospective cohort study
Maximilian B Bibok, Kristine Votova, Robert F Balshaw, et al.
Respiratory Medicine
|
January 14, 2026
Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States
Teresa De Marco, Carly J Paoli, Hayley D Germack, et al.
The Journal of Biological Chemistry
|
December 6, 2000
The DNMT1 target recognition domain resides in the N terminus
F D Araujo, S Croteau, A D Slack, et al.
Pulmonary Circulation
|
April 16, 2024
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States
Harrison W Farber, Hayley D Germack, Nicole S Croteau, et al.
Journal of Geriatric Oncology
|
January 16, 2020
Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab
Doran Ksienski, Elaine S Wai, Nicole S Croteau, et al.
Current Oncology (Toronto, Ont.)
|
June 4, 2020
Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab
A T Freeman, M Lesperance, E S Wai, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Therapeutic Advances in Neurological Disorders
|
March 18, 2025
Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
Robin L Avila, Nicole S Croteau, Fei Tang, et al.
Cureus
|
December 29, 2021
Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
Doran Ksienski, Pauline T Truong, Nicole S Croteau, et al.
Journal of Geriatric Oncology
|
October 16, 2021
Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab
Doran Ksienski, Pauline T Truong, Nicole S Croteau, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 6, 2021
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort
D Ksienski, P T Truong, E S Wai, et al.
BMC Health Services Research
|
February 28, 2018
Reducing time-to-unit among patients referred to an outpatient stroke assessment unit with a novel triage process: a prospective cohort study
Maximilian B Bibok, Kristine Votova, Robert F Balshaw, et al.
Respiratory Medicine
|
January 14, 2026
Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States
Teresa De Marco, Carly J Paoli, Hayley D Germack, et al.
The Journal of Biological Chemistry
|
December 6, 2000
The DNMT1 target recognition domain resides in the N terminus
F D Araujo, S Croteau, A D Slack, et al.
Pulmonary Circulation
|
April 16, 2024
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States
Harrison W Farber, Hayley D Germack, Nicole S Croteau, et al.
Journal of Geriatric Oncology
|
January 16, 2020
Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab
Doran Ksienski, Elaine S Wai, Nicole S Croteau, et al.
Current Oncology (Toronto, Ont.)
|
June 4, 2020
Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab
A T Freeman, M Lesperance, E S Wai, et al.
Page
of 3